Partner Partner presentationpresentation

Partner 1 – Partner 1 – Karolinska InstitutetKarolinska Institutet

• Ulrik Ringborg

• WP15 Ethical issues – WP leader Rolf Lewensohn KI

• WP16 Management – WP leader Ulrik Ringborg KI

Partner 2 – Partner 2 – Institut CurieInstitut Curie

• Sergio Roman-Roman

Participating in:• WP3 Early detection • WP4 Kinome analysis • WP6 Therapeutic strategies • WP8 Technological structures & resources for discovery • WP10 Biobanking • WP11 Epidemiology

Partner 3 – Partner 3 – Danish Cancer SocietyDanish Cancer Society

• Julio E. Celis

• WP1 Scientific coordination – WP leader J. E. Celis Participating partners:– DCS– INT– IGR– NKI– ERASMUS MC– UCAM– ECPC

Partner 4 – Partner 4 – Oslo University Hospital, Oslo University Hospital, RadiumhospitaletRadiumhospitalet• Anne-Lise Børresen-Dale

• WP3 Early detection – WP leader A-L. Børresen-Dale together with INTParticipating partners:

- KI - Inst Curie- DCS - OUS- INT - DKFZ- IGR - IARC- UOXF.HD - IEO- CHRIS - NIO- NKI - UCAM- IJB - LUMC

Partner 5 – Spanish National Cancer Research Centre

• Mariano Barbacid

• WP7 Mouse models – WP leader M. BarbacidParticipating partners:

- CNIO- NKI- UCAM

Partner 6 – Partner 6 – Fondazione IRCCS Istituto Nazionale Fondazione IRCCS Istituto Nazionale dei Tumoridei Tumori

• Marco A. Pierotti

• WP3 Early detection – WP leader M. A. Pierotti together with OUSParticipating partners:- KI - Inst Curie-DCS - OUS- INT - DKFZ- IGR - IARC- UOXF.HD - IEO- CHRIS - NIO- NKI - UCAM- IJB - LUMC

Partner 7 – Partner 7 – German Cancer Research German Cancer Research CentreCentre

• Otmar D. Wiestler

• WP11 Epidemiology – WP-leaders Hermann Brenner & Cornelia Ulrich Participating partners:- KI - Inst Curie- DCS - OUS- INT - DKFZ- IARC - IEO- CHRIS - NKI- UCAM - ERASMUS MC- IJB

Partner 8 – Partner 8 – Institut Gustave RoussyInstitut Gustave Roussy

• Alexander M. M. Eggermont

• WP6 Therapeutic strategies – WP-leader Thomas Tursz Participating partners: KI, Inst Curie, DCS, OUS, CNIO, INT, DKFZ, IGR, UOXF.HD, IEO, CHRIS, NIO, NKI, ERASMUS MC, UCAM, IJB, VHIO, EORTC

• WP12 Quality assurance/designation – WP-leader Mahasti Saghatchian together with NKIParticipating partners: IGR, IEO, NKI, OECI

Partner 9 – Partner 9 – International Agency for Research International Agency for Research on Cancer on Cancer • Christopher Wild

• WP2 Prevention – WP leader C. WildParticipating partners: IGR, IEO, NKI, OECI

Partner 10 – Partner 10 – Oxford Cancer CentreOxford Cancer Centre

• Nicholas La Thangue

Participating in: • WP3 Early detection • WP6 Therapeutic strategies • WP8 Technological structures &

resources for discovery

Partner 11 – Partner 11 – Istituto Europeo di OncologiaIstituto Europeo di Oncologia

• Umberto Veronesi

Participating in:• WP2 Prevention • WP3 Early detection • WP6 Therapeutic strategies • WP8 Technological structures &

resources for discovery • WP10 Biobanking • WP11 Epidemiology • WP12 Quality assurance/designation

Partner 12 – Partner 12 – Christie Foundation TrustChristie Foundation Trust

• Nicholas Jones

Participating in:• WP2 Prevention • WP3 Early detection • WP6 Therapeutic strategies • WP10 Biobanking • WP11 Epidemiology

Partner 13 – Partner 13 – National Institute of Oncology National Institute of Oncology

• Miklós Kasler

Participating in:• WP3 Early detection • WP6 Therapeutic strategies • WP8 Technological structures and resources for discovery • WP10 Biobanking

Partner 14 - Partner 14 - Netherlands Cancer InstituteNetherlands Cancer Institute

• Anton Berns

• WP4 Kinome analysis – WP leader René Bernards Participating partners: IGR, IEO, NKI, OECI

• WP8 Technological structures & resources for discovery – WP leader René Bernards, Participating partners: KI, Inst Curie, DCS, OUS, CNIO,

INT, DKFZ, IGR, UOXF.HD, IEO, NIO, NKI, EMC, UCAM

• WP12 Quality assurance/designation –WP leader Wim van Harten together with IGRParticipating partners: IGR, IEO, NKI, OECI

Partner 15 – Partner 15 – Erasmus University Medical Centre Erasmus University Medical Centre RotterdamRotterdam

• Alexander M.M. Eggermont

• WP10 Biobanking – WP leader Peter Riegman Participating partners:

- KI - Inst Curie- OUS - CNIO- INT - IARC- IEO - CHRIS- NIO - NKI- EMC - UCAM- FIVO - OECI

Partner 16 – Partner 16 – University of Cambridge, Dept of University of Cambridge, Dept of OncologyOncology• Carlos Caldas

Participating in:• WP3 Early detection • WP4 Kinome analysis • WP6 Therapeutic strategies • WP7 Mouse models • WP8 Technological structures &

resources for discovery • WP10 Biobanking • WP11 Epidemiology

Partner 17 – Partner 17 – Institut Jules BordetInstitut Jules Bordet

• Dominique de Valeriola

Participating in:• WP3 Early detection • WP6 Therapeutic strategies • WP11 Epidemiology

Partner 18 – Partner 18 – European Molecular Biology European Molecular Biology LaboratoryLaboratory• Jan Korbel

• WP9 Bioinformatics – WP leader Jan KorbelParticipating partners:- KI- IGR- EMC- EMBL

Partner 19 – Partner 19 – The Institute of Cancer The Institute of Cancer ResearchResearch• Alan Ashworth

Participating in:• WP5 Targeting the DNA damage response

Partner 20 – Partner 20 – Leiden University Medical Leiden University Medical CentreCentre• Nelleke Gruis

Participating in:• WP2 Prevention • WP3 Early detection

Partner 21 – Partner 21 – Fundacíon Institutio Valencian de Fundacíon Institutio Valencian de OncologiaOncologia

• Antonio Llombart Bosch

Participating in:• WP10 Biobanking

Partner 22 – Partner 22 – Istituto Tumori ”Giovanni Istituto Tumori ”Giovanni Paolo II”Paolo II”

• Angelo Paradiso

• WP13 Education – WP leader Angelo ParadisoParticipating partners: - NCI Bari- ECCO- OECI

Partner 23 – Partner 23 – Vall d´Hebron Insitute of Vall d´Hebron Insitute of OncologyOncology• José Baselga

Participating in:• WP6 Therapeutic strategies

Partner 24 – Partner 24 – eeCancerCancer

• Gordon McVie

• WP14 Communication and dissemination – WP leader Gordon McVieParticipating partners:- ECMS- ECCO- OECI- ECPC

Partner 25 –Partner 25 –European CanCer OrganisationEuropean CanCer Organisation

• Michel Ballieu

Participating in:• WP1 Scientific coordination, oncopolicy • WP13 Education • WP14 Communication and dissemination

Partner 26 –Partner 26 –Organisation of the Organisation of the European Cancer InstitutesEuropean Cancer Institutes

• Marco A. Pierotti & Claudio Lombardo

Participating in :• WP10 Biobanking • WP12 Quality assessment, accreditation and metrics • WP13 Education • WP14 Communication and dissemination

Partner 27 – Partner 27 – European Cancer Patient European Cancer Patient CoalitionCoalition

• Tom Hudson & Denis Horgan

Participating in:• WP1 Scientific coordination • WP14 Communication & dissemination

Partner 28 – Partner 28 – European Organisation of European Organisation of Research & Treatment of Research & Treatment of CancerCancer• Françoise Meunier

Participating in:• WP1 Scientific Coordination • WP6 Therapeutic Strategies • WP10 Biobanking